---
document_datetime: 2025-12-29 08:03:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dzuveo.html
document_name: dzuveo.html
version: success
processing_time: 0.1099856
conversion_datetime: 2025-12-30 10:28:00.722199
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dzuveo

[RSS](/en/individual-human-medicine.xml/66422)

##### Authorised

This medicine is authorised for use in the European Union

sufentanil Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Dzuveo](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Dzuveo is an opioid pain medicine used to treat moderate to severe pain in adults.

It is a 'hybrid medicine'. This means that it is similar to a 'reference medicine' (called Sufenta Forte) containing the same active substance. The difference between the products is that Dzuveo is available as sublingual tablets (tablets to be dissolved under the tongue) while the reference medicine is a solution for injection.

Dzuveo contains the active substance sufentanil.

Expand section

Collapse section

## How is Dzuveo used?

Dzuveo is available as 30 µg sublingual tablets. Using a disposable applicator, the healthcare professional should place one tablet under the patient's tongue and leave it to dissolve. The tablet must not be chewed or swallowed.

Patients should not eat or drink and should talk as little as possible for the 10 minutes after taking the tablet. They can be given the tablets as needed but should wait at least one hour after one tablet before having another. Dzuveo should not be used for more than 48 hours.

Dzuveo can only be obtained with a prescription. It should be given by a healthcare professional experienced in treating pain and in a place (such as a hospital) where the patient can be monitored. For more information about using Dzuveo, see the package leaflet or contact your doctor or pharmacist.

## How does Dzuveo work?

The active substance in Dzuveo, sufentanil, is an opioid that works by attaching to receptors (targets) in the brain known as ?-opioid receptors. Attaching to these receptors in the brain helps relieve the patient's pain.

## What benefits of Dzuveo have been shown in studies?

Two main studies have shown that Dzuveo left to dissolve under the tongue is effective at reducing severe pain following surgeries. Both studies used a pain rating scale known as SPID12 which tracks reduction in pain over 12 hours.

In the first study in 163 patients who had undergone abdominal surgery, pain reduced by 26 points with Dzuveo compared with 13 points with placebo (a dummy treatment). In the second study in 101 patients after foot surgery, pain reduced by around 6 points with Dzuveo and increased by around 7 points with placebo.

## What are the risks associated with Dzuveo?

The most serious side effects with sufentanil are severe breathing problems, which occur in around 6 people in 1,000. The most common side effects (which may affect more than 1 in 10 people) are nausea, vomiting and fever.

Dzuveo must not be used in patients with serious lung or breathing problems. For the full list of side effects and restrictions with Dzuveo, see the package leaflet.

## Why is Dzuveo authorised in the EU?

Studies show that Dzuveo is effective at reducing severe pain following surgeries. The side effects seen with Dzuveo are those expected with opioids, and are considered manageable. The European Medicines Agency therefore decided that Dzuveo's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Dzuveo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dzuveo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Dzuveo are continuously monitored. Side effects reported with Dzuveo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Dzuveo

Dzuveo received a marketing authorisation valid throughout the EU on 25 June 2018.

Dzuveo : EPAR - Summary for the public

Reference Number: EMA/283761/2018

English (EN) (82.96 KB - PDF)

**First published:** 18/07/2018

**Last updated:** 18/07/2018

[View](/en/documents/overview/dzuveo-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-936)

български (BG) (101.51 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/bg/documents/overview/dzuveo-epar-summary-public_bg.pdf)

español (ES) (83.05 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/es/documents/overview/dzuveo-epar-summary-public_es.pdf)

čeština (CS) (97.1 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/cs/documents/overview/dzuveo-epar-summary-public_cs.pdf)

dansk (DA) (79.3 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/da/documents/overview/dzuveo-epar-summary-public_da.pdf)

Deutsch (DE) (81.69 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/de/documents/overview/dzuveo-epar-summary-public_de.pdf)

eesti keel (ET) (80.18 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/et/documents/overview/dzuveo-epar-summary-public_et.pdf)

ελληνικά (EL) (106.55 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/el/documents/overview/dzuveo-epar-summary-public_el.pdf)

français (FR) (83.64 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/fr/documents/overview/dzuveo-epar-summary-public_fr.pdf)

hrvatski (HR) (91.96 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/hr/documents/overview/dzuveo-epar-summary-public_hr.pdf)

italiano (IT) (80.51 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/it/documents/overview/dzuveo-epar-summary-public_it.pdf)

latviešu valoda (LV) (96.35 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/lv/documents/overview/dzuveo-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (96.61 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/lt/documents/overview/dzuveo-epar-summary-public_lt.pdf)

magyar (HU) (93.64 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/hu/documents/overview/dzuveo-epar-summary-public_hu.pdf)

Malti (MT) (98.36 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/mt/documents/overview/dzuveo-epar-summary-public_mt.pdf)

Nederlands (NL) (79.76 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/nl/documents/overview/dzuveo-epar-summary-public_nl.pdf)

polski (PL) (98.37 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/pl/documents/overview/dzuveo-epar-summary-public_pl.pdf)

português (PT) (82.09 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/pt/documents/overview/dzuveo-epar-summary-public_pt.pdf)

română (RO) (95.52 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/ro/documents/overview/dzuveo-epar-summary-public_ro.pdf)

slovenčina (SK) (96.17 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/sk/documents/overview/dzuveo-epar-summary-public_sk.pdf)

slovenščina (SL) (92.55 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/sl/documents/overview/dzuveo-epar-summary-public_sl.pdf)

Suomi (FI) (81.84 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/fi/documents/overview/dzuveo-epar-summary-public_fi.pdf)

svenska (SV) (79.36 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/sv/documents/overview/dzuveo-epar-summary-public_sv.pdf)

Dzuveo : EPAR - Risk-management-plan summary

English (EN) (572.99 KB - PDF)

**First published:** 18/07/2018

**Last updated:** 29/05/2024

[View](/en/documents/rmp-summary/dzuveo-epar-risk-management-plan-summary_en.pdf)

## Product information

Dzuveo : EPAR - Product Information

English (EN) (490.08 KB - PDF)

**First published:** 18/07/2018

**Last updated:** 12/09/2024

[View](/en/documents/product-information/dzuveo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-145)

български (BG) (613.13 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/bg/documents/product-information/dzuveo-epar-product-information_bg.pdf)

español (ES) (482.52 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/es/documents/product-information/dzuveo-epar-product-information_es.pdf)

čeština (CS) (562.25 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/cs/documents/product-information/dzuveo-epar-product-information_cs.pdf)

dansk (DA) (497.96 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/da/documents/product-information/dzuveo-epar-product-information_da.pdf)

Deutsch (DE) (496 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/de/documents/product-information/dzuveo-epar-product-information_de.pdf)

eesti keel (ET) (487.02 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/et/documents/product-information/dzuveo-epar-product-information_et.pdf)

ελληνικά (EL) (614.83 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/el/documents/product-information/dzuveo-epar-product-information_el.pdf)

français (FR) (488.03 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/fr/documents/product-information/dzuveo-epar-product-information_fr.pdf)

hrvatski (HR) (549 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/hr/documents/product-information/dzuveo-epar-product-information_hr.pdf)

íslenska (IS) (468.78 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/is/documents/product-information/dzuveo-epar-product-information_is.pdf)

italiano (IT) (506.94 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/it/documents/product-information/dzuveo-epar-product-information_it.pdf)

latviešu valoda (LV) (567.89 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/lv/documents/product-information/dzuveo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (579.2 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/lt/documents/product-information/dzuveo-epar-product-information_lt.pdf)

magyar (HU) (593.29 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/hu/documents/product-information/dzuveo-epar-product-information_hu.pdf)

Malti (MT) (628.91 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/mt/documents/product-information/dzuveo-epar-product-information_mt.pdf)

Nederlands (NL) (506.47 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/nl/documents/product-information/dzuveo-epar-product-information_nl.pdf)

norsk (NO) (457.61 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/no/documents/product-information/dzuveo-epar-product-information_no.pdf)

polski (PL) (600.23 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/pl/documents/product-information/dzuveo-epar-product-information_pl.pdf)

português (PT) (485.22 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/pt/documents/product-information/dzuveo-epar-product-information_pt.pdf)

română (RO) (580.65 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/ro/documents/product-information/dzuveo-epar-product-information_ro.pdf)

slovenčina (SK) (580.18 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/sk/documents/product-information/dzuveo-epar-product-information_sk.pdf)

slovenščina (SL) (559.58 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/sl/documents/product-information/dzuveo-epar-product-information_sl.pdf)

Suomi (FI) (456.52 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/fi/documents/product-information/dzuveo-epar-product-information_fi.pdf)

svenska (SV) (465.36 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

12/09/2024

[View](/sv/documents/product-information/dzuveo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0012 02/08/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dzuveo : EPAR - All Authorised presentations

English (EN) (18.99 KB - PDF)

**First published:** 18/07/2018

**Last updated:** 18/07/2018

[View](/en/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-225)

български (BG) (34.18 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/bg/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_bg.pdf)

español (ES) (18.27 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/es/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (25.53 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/cs/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.52 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/da/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (18.15 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/de/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (18.14 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/et/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (34.03 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/el/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_el.pdf)

français (FR) (17.98 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/fr/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25.15 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/hr/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (18.3 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/is/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (18.79 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/it/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (29.8 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/lv/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (29.76 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/lt/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (24.17 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/hu/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (29.17 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/mt/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.75 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/nl/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (18.37 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/no/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_no.pdf)

polski (PL) (30.91 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/pl/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_pl.pdf)

português (PT) (18.15 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/pt/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_pt.pdf)

română (RO) (29.8 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/ro/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (25.07 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/sk/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (27.72 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/sl/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (18.05 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/fi/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (18.09 KB - PDF)

**First published:**

18/07/2018

**Last updated:**

18/07/2018

[View](/sv/documents/all-authorised-presentations/dzuveo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Dzuveo Active substance sufentanil citrate International non-proprietary name (INN) or common name sufentanil Therapeutic area (MeSH) Pain Anatomical therapeutic chemical (ATC) code N01AH03

### Pharmacotherapeutic group

Anesthetics

### Therapeutic indication

Dzuveo is indicated for the management of acute moderate to severe pain in adult patients.

## Authorisation details

EMA product number EMEA/H/C/004335 Marketing authorisation holder

Laboratoire Aguettant

Laboratoire Aguettant

Opinion adopted 26/04/2018 Marketing authorisation issued 25/06/2018 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Dzuveo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (132.38 KB - PDF)

**First published:** 08/10/2019

**Last updated:** 12/09/2024

[View](/en/documents/procedural-steps-after/dzuveo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Dzuveo-H-C-PSUSA-00002798-202111 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/833148/2022

English (EN) (128.17 KB - PDF)

**First published:** 26/10/2022

[View](/en/documents/scientific-conclusion/dzuveo-h-c-psusa-00002798-202111-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Dzuveo-H-C-PSUSA-00002798-201811 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/425728/2019

English (EN) (73.6 KB - PDF)

**First published:** 08/10/2019

[View](/en/documents/scientific-conclusion/dzuveo-h-c-psusa-00002798-201811-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Dzuveo : EPAR - Public assessment report

Reference Number: EMA/302958/2018

English (EN) (2.07 MB - PDF)

**First published:** 18/07/2018

**Last updated:** 18/07/2018

[View](/en/documents/assessment-report/dzuveo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Dzuveo

Adopted

Reference Number: EMA/CHMP/199029/2018

English (EN) (68.85 KB - PDF)

**First published:** 27/04/2018

**Last updated:** 27/04/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-dzuveo_en.pdf)

#### News on Dzuveo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2018) 27/04/2018

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 12/09/2024

## Share this page

[Back to top](#main-content)